# Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder

> **NCT01000493** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 132 (actual)

## Conditions studied

- Post-Traumatic Stress Disorder

## Interventions

- **DRUG:** orvepitant
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01000493
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-02
- **Primary completion:** 2010-06-28
- **Final completion:** 2010-06-28
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2017-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01000493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01000493, "Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01000493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*